HHS seems poised to exert control over USPSTF Ransohoff: The task force is the pinnacle of evidence-based medicine

Trump claims that autism is caused by Tylenol use during pregnancy, advises to “fight like hell not to take it”

In a press conference on Sept. 22, President Donald Trump, flanked by NIH Director Jay Bhattacharya, FDA Commissioner Marty Makary, HHS Secretary Robert Kennedy Jr., and CMS Administrator Mehmet Oz, touted that Tylenol use while pregnant is “probably” the cause of autism.

September 26, 2025

Vol.51 No.35

By Claire Marie Porter

Cancer Policy

After stormy Senate hearing, Trump offers tepid support for RFK Jr. while Kennedy family members call for his ouster

A fraught Senate Finance Committee hearing, where HHS Secretary Robert F. Kennedy Jr. clashed with Republicans and Democrats alike, has led to some fallout.

September 12, 2025

Vol.51 No.33

By Claire Marie Porter

Cancer Policy

Vinay Prasad regains role as FDA chief medical and scientific officer

Vinay Prasad has regained his role as FDA’s chief medical and scientific officer, according to an update on the agency’s website.

September 12, 2025

Vol.51 No.33

By Claire Marie Porter

Cancer Policy

FDA advances rare disease drug development with new evidence principles

FDA introduced the Rare Disease Evidence Principles to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.

As House committee gives NIH a small raise, cancer groups hope to maintain bipartisan support

The U.S. House Appropriations Committee has voted along party lines passing a bill that maintains current funding levels for NIH and NCI as part of its Fiscal Year 2026 Labor, HHS, Education and Related Agencies spending bill.

September 12, 2025

Vol.51 No.33

By Claire Marie Porter

Podcast

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

As NIH and NCI funding is negotiated in Congress, Paul W. Thurman felt compelled to crunch some numbers. He compared the U.S.’s cumulative funding for NCI to the funding slated for ICE—the latter of which vastly outweighs the former—and asked whether the funding priorities of the federal government are properly representing the nation’s mortality.

September 10, 2025

Vol.51 No.32

HHS seems poised to exert control over USPSTF

Ransohoff: The task force is the pinnacle of evidence-based medicine

YOU MAY BE INTERESTED IN

Trump claims that autism is caused by Tylenol use during pregnancy, advises to “fight like hell not to take it”

After stormy Senate hearing, Trump offers tepid support for RFK Jr. while Kennedy family members call for his ouster

Vinay Prasad regains role as FDA chief medical and scientific officer

FDA advances rare disease drug development with new evidence principles

As House committee gives NIH a small raise, cancer groups hope to maintain bipartisan support

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

Renew today!

Subscriber content

Never miss an issue!

Login